Unveiling the Potential Drug Target CCDC194: A tumor suppressor potential and discovery of tumor-related genes

Target Name: CCDC194

NCBI ID: G110806280

CCDC194

Other Name(s): coiled-coil domain containing 194 | Coiled-coil domain-containing protein 194

Unveiling the Potential Drug Target CCDC194: A tumor suppressor potential and discovery of tumor-related genes

Summary

Cancer cells are a serious challenge in modern medicine. The recurrence and drug resistance of tumors have always troubled the medical community. However, scientists have made a series of breakthroughs in the field of tumor suppressor gene research. Today, we are going to focus on a high-profile discovery: CCDC194, a tumor suppressor gene mutant located in the tumor suppressor gene P53, which may become a new target for cancer treatment in the future.

1. Background introduction

Tumor suppressor genes are genes in cells responsible for regulating important life processes such as cell cycle, growth and division. Under normal circumstances, tumor suppressor genes can effectively prevent abnormal cell proliferation. However, when tumor suppressor genes mutate, cells may lose control of proliferation, leading to tumor formation. P53 is one of the most important genes in the tumor suppressor gene family, and its mutations are closely related to the onset of various cancers.

2. Discovery of CCDC194

CCDC194, full name coiled-coil domain containing 194, is a tumor suppressor gene mutant located near the coding region of the P53 gene. Studies have found that mutations in CCDC194 can lead to loss of function of the P53 gene, making tumor cells resistant to growth factors and chemotherapy drugs. In addition, mutations in CCDC194 may also lead to tumor cell invasion and metastasis.

3. Cancer suppressor mechanism of CCDC194

The tumor suppressor mechanism of CCDC194 mainly involves the following aspects:

(1) Affect P53 gene expression

Studies have found that mutations in CCDC194 can affect the transcription and translation of the P53 gene. Specifically, mutations in CCDC194 lead to a decrease in the RNA level of the P53 gene, thereby preventing the normal expression of P53. This can lead to tumor cells becoming resistant to growth factors and chemotherapy drugs.

(2) Affecting the cycle of tumor cells

Mutations in CCDC194 may affect the cycle of tumor cells, leading to cell cycle abnormalities. Studies have found that mutations in CCDC194 can cause the tumor cell cycle to become longer and inhibit the regulation of cell cycle proteins. This may make it easier for tumor cells to evade killing by chemotherapy drugs.

(3) Promote the invasion and metastasis of tumor cells

Mutations in CCDC194 may affect tumor cell invasion and metastasis. Studies have found that mutations in CCDC194 lead to enhanced invasion and metastasis capabilities of tumor cells. This brings certain challenges to the transfer and treatment of tumor cells.

4. Clinical significance of CCDC194

CCDC194, as a tumor suppressor gene mutant, is of great significance for the treatment of cancer. First, mutations in CCDC194 may be a new drug target. Through the intervention of CCDC194, it is expected to develop more targeted drugs to treat cancer. In addition, mutations in CCDC194 may also bring new ideas for the treatment of tumor cells.

5 Conclusion

CCDC194, a tumor suppressor gene mutant located near the coding region of the tumor suppressor gene P53, has attracted widespread attention from scientists. Studies have found that mutations in CCDC194 can lead to loss of function of the P53 gene, making tumor cells resistant to growth factors and chemotherapy drugs. Through further research, CCDC194 may become a new target for the treatment of cancer in the future. Although there are currently no effective treatments for CCDC194, with the development of medical technology in the future, CCDC194 may become an important research topic.

Protein Name: Coiled-coil Domain Containing 194

The "CCDC194 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC194 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets